- Company
- Pfizer, Lilly, AbbVie engage in JAKi battle in KOR
- by Nho, Byung Chul Jul 3, 2023 05:47am
- Pfizer's Xeljanz and Lilly's Olumiant are engaged in an intense competition for sales in the JAK inhibitor market. According to the distribution data of pharmaceuticals, Xeljanz (including Xeljanz XR) recorded sales of KRW 15.5 billion won last year, while Olumiant recorded KRW 15.4 billion. Although Xeljanz maintained a slight lead,
- Company
- Illaris for 13 pts, re-challenge to enter insurance benefit
- by Eo, Yun-Ho Jul 3, 2023 05:45am
- Illaris, a treatment for vulva diseases with only 13 patients in Korea, will try again to enter the insurance benefit zone. According to related industries, Novartis Korea submitted an application for Ilaris' benefit in April and is under discussion. However, the registration process is still expected to be difficult. The drug has already und
- Company
- Imfinzi+Imjudo combo approved for liver cancer in KOR
- by Eo, Yun-Ho Jul 3, 2023 05:45am
- The immuno-oncology drug ‘Imfinzi’ added an indication in Korea and can be used in combination with ‘Imjudo’ in Korea. According to industry sources, AstraZeneca received approval for the combined use of Imfinzi+Imjudo from the Ministry of Food and Drug Safety on June 30th, immediately after receiving approval for its CTLA-4 inhibitin
- Policy
- Eval period for HCV treatment shortened to 12 weeks from 24
- by Lee, Hye-Kyung Jun 30, 2023 06:01am
- The evaluation period used to determine the efficacy of chronic hepatitis C treatments has been reduced in Korea. The Ministry of Food and Drug Safety (Minister Yu-Kyoung Oh) revised the 'Clinical Trial Evaluation Guidelines for Chronic Hepatitis C Treatments' on June 29 to align Korea’s clinical trial efficacy evaluation standards with
- Company
- Oral AML drug Onureg can be prescribed at general hospitals
- by Eo, Yun-Ho Jun 30, 2023 06:01am
- The oral acute myeloid leukemia (AML) treatment ‘Onureg’ can now be prescribed at general hospitals in Korea. According to industry sources, BMS Korea’s new AML drug Onureg tablet (azacytidine) has passed the drug committees of Asan Medical Center and Seoul National University Bundang Hospital and is also undergoing landing processes
- Policy
- Tx for combi of dementia/hyperlipidemia have increased
- by Lee, Tak-Sun Jun 30, 2023 06:01am
- The amount of claims for dementia treatment and hyperlipidemia has increased by more than 50% in the past two years. In the case of dementia treatment, it seems to have increased significantly as the elderly patients' visits to medical institutions decreased in 2020 due to COVID-19. The hyperlipidemia complex is interpreted as the amount of char
- Opinion
- [Reporter's view] Signs of concern about the Saxenda craze
- by Jun 29, 2023 05:56am
- Five years ago, there was a Saxenda craze in Korea. People rushed to the clinics because they could easily lose weight with self-injection once a day at home, and there were no central nervous system side effects, unlike existing obesity drugs, which are psychotropic drugs. The saying, 'There is no one in Gangnam who does not take Saxenda' w
- Company
- Unlisted Trajenta patents hinder early release of generics
- by Kim, Jin-Gu Jun 29, 2023 05:56am
- The patent challenges made for the early release of antidiabetic ‘Trajenta (linagliptin)’ is going through a rough patch. The patents that the original company registered with KIPO but not with the MFDS are acting as obstacles. For the generics companies that filed patent challenges, a prolonged dispute is now inevitable as they would hav
- Company
- SK Plasma supplies 39 billion worth of blood products
- by Jun 29, 2023 05:56am
- SK Plasma announced on the 28th that it will begin full-fledged production this month after receiving product approval for blood products (albumin and immunoglobulin) from the Singapore Health Authority (HSA). The company will independently supply a total of 30 million dollars (39 billion won) worth of blood derivatives over the next six yea
- Company
- RET-targeted Retevmo lands in Big 5 general hospitals in KOR
- by Eo, Yun-Ho Jun 29, 2023 05:56am
- The RET-targeted anticancer therapy ‘Retevmo’ may now be prescribed at the Big 5 hospitals in Korea. According to industry sources, Lilly Korea’s Retevmo (selpercatinib) passed the drug committees of all the Big 5 tertiary hospitals in Korea - Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary’s Hospital, Seoul
